Niraparib plays synergistic antitumor effects with NRT in a mouse ovarian cancer model with HRP
Niraparib could exert immune-reshaping effects, then acts synergistic antitumor effects with NRT in HRP ovarian cancer model. Our findings provide new ideas and rationale for combined immunotherapy in HRP ovarian cancer.
Authors
- Fumao Bai
- Xiaoping Su (ORCID: https://orcid.org/0000-0003-1824-943X)
- Haiying Liu (ORCID: https://orcid.org/0000-0001-6852-8256)
- Jiefang Lu
- Ping Duan (ORCID: https://orcid.org/0000-0002-1620-2032)
- Chengcheng Chen (ORCID: https://orcid.org/0000-0002-6015-5413)
- Binming Wang (ORCID: https://orcid.org/0009-0007-8333-3511)
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Lishui Central Hospital (CN)
- Lishui City People's Hospital (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1016/j.tranon.2024.102094
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00